drugset / Trial / NCT07025915

A Phase 1 Mass Balance Study of [¹⁴C]SSS17 in Healthy Chinese Males

NCT07025915 ↗

Phase 1 Not yet recruiting 6 enrolled Shenyang Sunshine Pharmaceutical Co., LTD.
NaSingle-groupOpen-labelOther

Summary

This study aims to evaluate the absorption, metabolism, and excretion of a single oral dose of \[¹⁴C\]SSS17 in healthy adult Chinese male subjects, elucidating its overall pharmacokinetic profile in humans to provide essential information for its rational clinical use.

Timeline

Start
2025-06
Primary completion
2025-07
Completion
2025-07

Drugs

EvaluationDrugModalityDoseRoute
Subject SSS17 Small molecule — Oral

Indications

No indication recorded.